Brief: Everest Medicines Posts HY Net Loss Of RMB383.1 Million
30/08/2021 16:04
Aug 30 (Reuters) - Everest Medicines Ltd 1952.HK :
* HY NET LOSS RMB383.1 MILLION VERSUS RMB623.5 MILLION
* HY ADJUSTED LOSS RMB303.1 MILLION VERSUS RMB245.9 MILLION
Further company coverage: 1952.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Everest Medicines
See all newsBrief: Everest Medicines Says NMPA Approves Cardamyst (Etripamil) NDA For PSVT In Adults In China
Brief: Everest Medicines Enters Commercialization Collaboration With Hainan Herui Pharmaceutical
Brief: Everest Medicines Says CBC Group Purchases 712,000 Everest Medicines Shares For Hk$19.2 Million From 16 To 17 June
Australia's Dimerix soars on commercialisation deal with Everest Medicines
Brief: Dimerix Ltd Licenses Dmx200 To Everest For China And Asia Region